Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study.

Oksuz S, Kınıkoglu O, Sariyar N, Ozdemir M, Isik D, Surmeli H, Ay S, Odabas H, Turan N

DOI: 10.1186/s12885-026-16037-8
Published: 2026 Apr 15
Container: BMC cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-026-16037-8,
  title = {Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study.},
  author = {Oksuz S and Kınıkoglu O and Sariyar N and Ozdemir M and Isik D and Surmeli H and Ay S and Odabas H and Turan N},
  year = {2026},
  journal = {BMC cancer},
  doi = {10.1186/s12885-026-16037-8},
  url = {https://doi.org/10.1186/s12885-026-16037-8}
}

RIS

TY  - JOUR
TI  - Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study.
AU  - Oksuz S
AU  - Kınıkoglu O
AU  - Sariyar N
AU  - Ozdemir M
AU  - Isik D
AU  - Surmeli H
AU  - Ay S
AU  - Odabas H
AU  - Turan N
PY  - 2026
JO  - BMC cancer
DO  - 10.1186/s12885-026-16037-8
UR  - https://doi.org/10.1186/s12885-026-16037-8
ER  -

APA

S, O., O, K., N, S., M, O., D, I., H, S., S, A., H, O., & N, T. (2026). Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study.. BMC cancer. https://doi.org/10.1186/s12885-026-16037-8

Source records

pubmed · retrieved 2026-09-26T00:21:44.133Z